奥精医疗(688613) - 2025 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of 223.51 million yuan, a year-on-year increase of 8.48%[2] - Net profit attributable to shareholders of the parent company reached 13.15 million yuan, a significant increase of 203.86% compared to the previous year[2] - The total assets at the end of the reporting period were 1,564.45 million yuan, reflecting a growth of 1.64% from the beginning of the period[4] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, was -0.915 million yuan, an improvement of 96.77% year-on-year[4] - The company’s basic earnings per share was 0.10 yuan, compared to -0.09 yuan in the previous year, marking a 207.03% increase[2] - The weighted average return on net assets increased by 1.84 percentage points to 0.93%[2] Operational Strategy - The company strengthened its production guarantee system to meet the increased demand from orthopedic artificial bone procurement[5] - The marketing strategy focused on regional market development and precise marketing, contributing to steady revenue growth[5] - The significant increase in operating profit and total profit was attributed to the recovery of long accounts receivable due to extended credit terms for distributors[7] Financial Data Disclaimer - Investors are advised to note that the financial data for 2025 is preliminary and unaudited, with final results to be confirmed in the annual report[8]